Investors

Press releases

2018/06/28

Medivir announces positive top-line results from the MIV-711 osteoarthritis phase IIa extension study

Read more
2018/06/18

Continued discussions with FDA on proposed remetinostat phase III design results in delay in planned start of study

Read more
2018/05/31

Phase I/II study design of birinapant in combination with Keytruda® to be presented on June 4 at the ASCO Annual Meeting

Read more

Presentations

Quarterly report presentations

Events

2018/07/25

Interim Report January-June 2018

Read more
2018/09/10

Nordic Life Sciences Day

Read more
2018/10/26

Interim Report January - September 2018

Read more

Corporate Governance

Medivir Corporate Governance documention.

Annual General Meeting

Documentation from Medivir's Annual General Meetings.